The Cardiolipin Antibody (ACL-IgM) test is a blood test used to detect the presence of IgM-type antibodies against cardiolipin, a phospholipid found in cell membranes. These antibodies are part of a group called antiphospholipid antibodies, which can increase the risk of abnormal blood clot formation. The test is primarily used to help diagnose antiphospholipid syndrome (APS), particularly in patients with a history of unexplained blood clots, recurrent miscarriages, or certain autoimmune disorders like systemic lupus erythematosus (SLE). Elevated ACL-IgM levels may indicate an increased risk for thrombosis or pregnancy complications. Results are interpreted along with other antibody tests, such as ACL-IgG and Lupus Anticoagulant, for a comprehensive assessment of clotting risk and autoimmune activity.Reports On : With 90 minuteSample Type : BloodFasting…

The Cardiolipin Antibody (ACL-IgG) test is a blood test that detects the presence of IgG antibodies directed against cardiolipin, a phospholipid found in cell membranes. Elevated levels of these antibodies may indicate an increased risk for autoimmune conditions such as antiphospholipid syndrome, systemic lupus erythematosus, or recurrent miscarriages. This test helps in assessing unexplained blood clotting, thrombosis, or pregnancy complications. ACL-IgG is often measured alongside other antibodies, such as ACL-IgM and lupus anticoagulant, to provide a comprehensive evaluation of autoimmune and thrombotic risk. Results guide clinical management and treatment planning.Reports On : With 12 HoursSample Type : BloodFasting : Not Required Click Here To Book A Test

The Cardiolipin Antibody (ACL-IgA) test measures the presence of IgA-type antibodies directed against cardiolipin, a phospholipid found in cell membranes. Elevated levels of these antibodies may indicate an increased risk of autoimmune disorders, particularly antiphospholipid syndrome (APS), which can lead to abnormal blood clotting, recurrent miscarriages, or vascular complications. This test is often performed alongside ACL-IgG and ACL-IgM antibodies to provide a comprehensive assessment of autoimmune-related coagulation risks. Results help clinicians diagnose, monitor, and manage patients with suspected autoimmune or thrombotic disorders.Reports On : With 24 HoursSample Type : BloodFasting : Not Required Click Here To Book A Test